New cell therapy trial offers hope for tough autoimmune cases

NCT ID NCT07049081

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 15 times

Summary

This study tests a new treatment called LUCAR-G79 for people with autoimmune diseases like lupus that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack disease-causing cells. The goal is to see if it is safe and can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    NOT_YET_RECRUITING

    Nantong, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Zhongshan Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Third The People's Hospital of Bengbu

    RECRUITING

    Bengbu, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The second Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi’an, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.